Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Avillion's positive Phase 2 trial of tri-specific Nanobody® sonelokimab (M1095) in chronic psoriasis published in The Lancet


News provided by

Avillion

23 Apr, 2021, 08:00 GMT

Share this article

Share toX

Share this article

Share toX

-  All Primary and Secondary endpoints met with high statistical significance

-  Sonelokimab is a novel, investigational tri-specific Nanobody® that neutralizes both IL-17A and IL-17F

-  Trial completed under a co-development agreement between Avillion and Merck KGaA Darmstadt, Germany

LONDON, April 23, 2021 /PRNewswire/ -- Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, announces that its positive Phase 2 trial of sonelokimab (M1095)  in patients with chronic psoriasis has been published in the prestigious peer-reviewed medical journal The Lancet (Papp et al. ref. 1).

Sonelokimab is a novel tri-specific Nanobody® targeting IL 17A and IL-17F that also has an extended half-life and enhanced biodistribution through engineered binding affinity to albumin. The IL-17 family of cytokines induce and mediate proinflammatory responses and are implicated in a variety of autoimmune diseases in dermatology and rheumatology. 

The Phase 2 trial with sonelokimab was conducted by Avillion under a co-development agreement with Merck KGaA Darmstadt, Germany and completed ahead of schedule in 2020 (ClinicalTrials.gov Identifier: NCT03384745).

The trial evaluated four dose regimens of sonelokimab and included both placebo and an active control arm of the IL-17A inhibitor secukinumab. 313 patients were randomized (n=51–53 for each group) with demographic and baseline characteristics generally similar between arms. The trial enrolled patients at 41 investigator sites in North America and Europe.

The trial met its primary efficacy endpoint based on Investigator's Global Assessment (IGA) at week 12 with clinically meaningful and statistically significant results for all tested doses (p<0.001). All secondary endpoints – Psoriasis Area and Severity Index (or PASI 75, PASI 90, and PASI 100) at week 12 – were also met with high statistical significance (p≤0.002).

Sonelokimab was also found to be generally well tolerated with a safety profile in line with other biologic therapies for psoriasis at all doses tested.

At the highest dose, sonelokimab provided rapid and meaningful responses including:

  • PASI 90 responses in approximately 1/3 of patients at week 4
  • PASI 90 responses in approximately 8 of 10 patients at week 12
  • PASI 100 responses or total skin clearance in almost 6 of 10 of patients at week 24

The majority of adverse events (AEs) reported during the placebo-controlled period were mild to moderate. Approximately half of patients reported one or more AEs, with the most frequent (incidence ≥5%) being nasopharyngitis (13.5%) and pruritus (6.7%). Five patients treated with sonelokimab experienced serious AEs (none related to study drug) and three discontinued due to an AE. Over one year, sonelokimab safety was similar to secukinumab with the possible exception of manageable Candida infections.

Prof. Dr. Kristian Reich, Professor for Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf and an internationally recognised dermatology expert, played a pivotal role in designing and implementing the study and interpreting the data.

Commenting on the results, Prof. Dr. Reich said: "Chronic psoriasis has a significant negative impact on the health and quality of life of patients and effective new treatments are in great need. The positive results from this trial with sonelokimab are very encouraging as they demonstrate the speed of effect, durability and tolerability of this novel tri-specific nanobody approach targeting both IL-17A and IL-17F in patients with plaque-type psoriasis. Phase 3 studies are clearly warranted to confirm the benefits of sonelokimab and its potential to significantly improve upon existing therapeutic options."

Allison Jeynes, MD, Chief Executive Officer of Avillion, added: "We are extremely grateful to the investigators and patients across North American and Europe who participated in the Phase 2 trial with sonelokimab. Its efficient conduct and positive conclusion are a great example of the expertise, capabilities and value-add that Avillion brings to advance its partner's candidates through late-stage clinical development."

Top-line results from this study were first announced on 10 September 2020 and subsequently presented in the Late-Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2020 Virtual Congress in October 2020.

Reference

1.  K.A. Papp, M. Weinberg, A. Morris, K. Reich. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. The Lancet (2021);397: 1564-75.

About sonelokimab (M1095)

The Anti-IL-17 A/F Nanobody® sonelokimab is an investigational tri-specific half-life-extended Nanobody that is thought to neutralise both IL-17A and IL-17F with the potential to treat inflammatory diseases. Due to the small size and unique structure of Nanobodies®, they could be an ideal building block for a new generation of novel biological drugs.

Merck KGaA Darmstadt, Germany acquired full, exclusive rights to anti-IL-17 A/F Nanobody® through a global development and commercialisation deal with Ablynx in 2013. Avillion entered into a co-development agreement with Merck KGaA Darmstadt, Germany for the Phase 2 and Phase 3 development of sonelokimab in March 2017.

About Psoriasis

Psoriasis is a chronic, relapsing, inflammatory skin disease that affects approximately 8 million people in the US and 125 million worldwide1; 2-3 % of the total population have psoriasis, according to the World Psoriasis Day consortium. The exact causes leading to the development of psoriasis are not known yet, but some factors have been shown to play an important role, such as genetic predisposition or the presence of other diseases (comorbidities) or risk factors. Various treatments are available, but there is not yet a definite cure, meaning that psoriasis patients require a lifelong treatment. Psoriasis can begin at any age, and people affected are at an increased risk of developing other serious health conditions. Psoriasis has a significant impact on quality of life and on psychological health.

1 National Psoriasis Foundation. Statistics. https://www.psoriasis.org/content/statistics . Accessed October 2020

About the sonelokimab (M1095) Phase 2 trial (NCT identifier NCT03384745)

The trial is a Phase 2b randomized, double-blind, placebo controlled, multi-centre study designed to assess sonelokimab 's efficacy, safety and tolerability in subjects with moderate to severe chronic plaque-type psoriasis. The trial enrolled 313 patients (age 18-75) with:

  • chronic plaque psoriasis for at least six months
  • an Investigator's Global Assessment (IGA) score ≥3
  • involved body surface area (BSA) ≥10%, and
  • Psoriasis Area and Severity Index (PASI) ≥12 at screening and at baseline.

Patients were randomised to one of four experimental arms (n=51–53 for each group) exploring four dose regimens with sonelokimab, or a placebo comparator arm or an active reference arm (secukinumab).

The study consisted of a 12-week placebo-controlled period, followed by a 12-week dose optimization part and a dose individualization part from week 24–52.

During the first 12 weeks, patients received placebo, sonelokimab 30 mg, 60 mg, or 120 mg at weeks 0, 2, 4, and 8 (denoted normal load); sonelokimab 120 mg at weeks 0, 2, 4, 6, 8 and 10 (denoted augmented load); or secukinumab 300 mg (weeks 0, 1, 2, 3, 4 and 8. 

From weeks 12–24 (maintenance/escalation), patients randomized to 30 or 60 mg sonelokimab with an IGA score of >1 at week 12 were escalated to 120 mg once monthly (q4w), those receiving placebo were switched to 120 mg (weeks 12, 14, 16 and q4w), and patients receiving 120 mg normal load) and 120 mg augmented load) were treated q8w and q4w, respectively.

The primary endpoint was achievement of an IGA response (i.e. IGA score of 0 or 1, with an IGA reduction of at least 2 points from baseline) vs. placebo. IGA is the Investigator's assessment of the extent of psoriasis, with 0 = clear of psoriasis, 1 = almost clear, 2 = mild psoriasis, 3 = moderate psoriasis, and 4 = severe psoriasis (the worst assessment on this scale).

Secondary endpoints included PASI 75 (reduction in PASI burden by at least 75%), PASI 90 (reduction in PASI burden by at least 90%) and PASI 100 (psoriasis has completely cleared) at week 12 compared to baseline.

The trial enrolled patients at 41 investigator sites in North America and Europe.

About Avillion

Avillion offers pharma partners an innovative model providing additional funding and clinical development expertise, to maximise the potential of new and existing assets. With deal sizes ranging from $50M–$600M, Avillion takes on the full clinical and regulatory risk, focusing on the speed and quality of trial execution. Typically supporting programs post proof-of-concept through to registration and with an agnostic approach to therapy area, Avillion prides itself in adding value around operational expertise while being backed by established long-term investors.

Avillion was founded in 2012 and is backed by Abingworth and Blackstone Life Sciences (previously Clarus Ventures). Blackstone Life Sciences and Royalty Pharma funded the sonelokimab program. 

For more information, please visit us at www.avillionllp.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.